Please select the option that best describes you:

Would you add neoadjuvant pembrolizumab to chemotherapy in a premenopausal female with T2N1 breast cancer that is weakly ER or PR positive?  



Answer from: Medical Oncologist at Academic Institution
Comments
Medical Oncologist at NYU Winthrop Hospital
KEYNOTE-522:- eligibility triple negative. I will...
Sign in or Register to read more